David A Sallman
Overview
Explore the profile of David A Sallman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, et al.
J Natl Compr Canc Netw
. 2025 Mar;
23(3):66-75.
PMID: 40073835
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has...
2.
Zeidner J, Sallman D, Recher C, Daver N, Leung A, Hiwase D, et al.
Blood
. 2025 Feb;
PMID: 40009500
Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine...
3.
Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, et al.
Hemasphere
. 2025 Feb;
9(2):e70086.
PMID: 39944234
We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors of response in low-risk (LR) myelodysplastic syndrome (MDS) patients. We evaluated 331 anemic patients treated with...
4.
Moseley A, LeBlanc M, Freidlin B, Shallis R, Zeidan A, Sallman D, et al.
Clin Trials
. 2025 Jan;
:17407745241304065.
PMID: 39815460
Background/aims: Randomized clinical trials often use stratification to ensure balance between arms. Analysis of primary endpoints of these trials typically uses a "stratified analysis," in which analyses are performed separately...
5.
Tremblay D, Csizmar C, DiNardo C, Ball S, Rippel N, Hammond D, et al.
Leukemia
. 2024 Nov;
39(1):257-260.
PMID: 39533069
No abstract available.
6.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
7.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
8.
Jain A, Volpe V, Wang C, Ball S, Tobon K, Chan O, et al.
Ann Hematol
. 2024 Sep;
104(1):307-315.
PMID: 39243312
Introduction: We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA + Ven) who achieved complete remission (CR), complete remission with partial hematologic...
9.
Sallman D, Stahl M
Blood
. 2024 Sep;
PMID: 39236289
Despite advances in the treatment paradigm of patients with acute myeloid leukemia (AML), TP53 mutated AML represents a molecular subgroup that has failed to improve with an overall survival around...
10.
Ben-Crentsil N, Mohammed Ismail W, Balasis M, Newman H, Quintana A, Binder M, et al.
Cancer Discov
. 2024 Aug;
14(12):2509-2531.
PMID: 39189614
This work identifies MALAT1 as a requisite downstream effector of oncogenic feedforward inflammatory circuits necessary for the development of TET2-mutated CH and fulminant myeloid malignancy. We elucidate a novel mechanism...